1,411 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD http://www.zacks.com/stock/news/642646/global-bloods-gbt-oxbryta-secures-fda-approval-for-scd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-642646 Nov 27, 2019 - Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.
CRISPR vs. Gene Therapy Round 1: What Investors Need to Know https://www.fool.com/investing/2019/11/26/crispr-vs-gene-therapy-round-1-what-investors-need.aspx?source=iedfolrf0000001 Nov 26, 2019 - There’s still a long way to go, but the newcomer is off to a good start.
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal http://www.zacks.com/stock/news/638202/4-big-drug-stocks-ripe-for-takeover-after-nvs-mdco-deal?cid=CS-ZC-FT-analyst_blog|industry_focus-638202 Nov 26, 2019 - Here are four stocks that boast promising prospects and are most likely to be takeout targets.
Roche's NDA for SMA Drug Risdiplam Gets Priority Review http://www.zacks.com/stock/news/637403/roches-nda-for-sma-drug-risdiplam-gets-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-637403 Nov 25, 2019 - The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.
Novartis (NVS) to Acquire The Medicines Company for $9.7B http://www.zacks.com/stock/news/636880/novartis-nvs-to-acquire-the-medicines-company-for-%2497b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-636880 Nov 25, 2019 - Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.
The Medicines Company to be Acquired by Novartis for $9.7B http://www.zacks.com/stock/news/636814/the-medicines-company-to-be-acquired-by-novartis-for-%2497b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-636814 Nov 25, 2019 - The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.
A Day of Mergers: TIF, AMTD, MDCO & More http://www.zacks.com/stock/news/636974/a-day-of-mergers-tif-amtd-mdco-more?cid=CS-ZC--economic_highlights-636974 Nov 25, 2019 - A Day of Mergers: TIF, AMTD, MDCO & More
Biggest Merger Monday in Awhile: TIF, AMTD, MDCO & More http://www.zacks.com/stock/news/636972/biggest-merger-monday-in-awhile-tif-amtd-mdco-more?cid=CS-ZC-FT-ahead_of_wall_street-636972 Nov 25, 2019 - While Tiffany's agrees to terms with French luxury brand LVMH, Schwab buys Ameritrade, Novartis takes Medicines Co. and more.
Merck's Heart Failure Candidate Meets Goal in Phase III Study http://www.zacks.com/stock/news/627569/mercks-heart-failure-candidate-meets-goal-in-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-627569 Nov 19, 2019 - Merck (MRK) and German partner Bayer's vericiguat reduces the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure.
Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex http://www.zacks.com/stock/news/627382/aerie-to-acquire-dry-eye-disease-focused-pharma-avizorex?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-627382 Nov 19, 2019 - Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.

Pages: 12345678910...142

<<<Page 5>